Boston, MACIK 15958555 filings on record
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeLargest positions by weight
54 positions · Q4 2025
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Harrow Inc | 3.90M | $191.34M | 25.2% | 0 | Held |
| 2 | Liquidia Corporation | 2.44M | $84.98M | 11.2% | −180.0K | Reduced |
| 3 | Eton Pharmaceuticals Inc | 2.86M | $48.36M | 6.4% | 0 | Held |
| 4 | Rhythm Pharmaceuticals Inc |
| 330.0K |
| $35.32M |
| 4.7% |
| −131.7K |
| Reduced |
| 5 | Apogee Therapeutics Inc | 388.3K | $29.31M | 3.9% | +25.0K | Added |
| 6 | Sanuwave Health Inc | 981.3K | $29.28M | 3.9% | +1.3K | Added |
| 7 | Stoke Therapeutics Inc | 695.0K | $22.06M | 2.9% | +13.0K | Added |
| 8 | Ocular Therapeutix Inc | 1.59M | $19.36M | 2.6% | 0 | Held |
| 9 | Sol Gel Technologies | 453.7K | $19.12M | 2.5% | +248.9K | Added |
| 10 | Cg Oncology Inc | 410.0K | $17.02M | 2.2% | 0 | Held |
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio